Outcomes in patients with cardiac amyloidosis undergoing heart transplantation : the eurotransplant experience / Martin J. Kraus, Jacqueline M. Smits, Anna L. Meyer, Agita Strelniece, Arne van Kins, Udo Boeken, Alexander Reinecke, Zdenek Provaznik, Oliver Van Caenegem, Arnaud Ancion, Michael Berchtold-Herz, Johan J.A. Van Cleemput, Axel Haverich, Guenther Laufer, Jan Gummert, Matthias Karck, Gregor Warnecke, Philip W. Raake, Norbert Frey, and Michael M. Kreusser
Background - When advanced heart failure occurs in cardiac amyloidosis, prognosis is poor. In this setting heart transplantation (HTX) is a treatment option for selected patients. We here present the results of post-transplantation outcomes in cardiac amyloidosis within the Eurotransplant area, investigating possible predictors of survival. - Methods - Of 115 patients undergoing HTX due to cardiac amyloidosis in the Eurotransplant region between November 1987 and May 2020, detailed assessment prior to transplantation was available in 85 patients. The present study was conducted in a retrospective approach. Primary endpoint was mortality after HTX. Baseline variables were entered in a Cox proportional hazards model with the primary endpoint as a dependent variable. - Results - Median overall survival following HTX was 6.3 years in the overall collective and the subgroup. Univariate Cox proportional hazards model revealed a significant relationship between overall survival and the transplantation period (2008 to 2020 vs 1987 to 2007; median survival 9.7 years vs 1.8 years, hazard ratio 0.45, p = 0.01). Further predictors were albumin concentration (hazard ratio 0.92, p < 0.001), and systolic blood pressure (hazard ratio 0.96, p < 0.001). The transplant period as well as albumin concentration remained significant independent predictors in the AL sub cohort in a multivariate Cox proportional hazards model. - Conclusions - HTX is a viable treatment option for patients at an advanced stage of cardiac amyloidosis as overall survival after transplantation has improved in the modern age. Patients at a very advanced stage of the disease, indicated by low serum albumin and blood pressure, show worse outcomes following HTX. Optimal timing and careful patient selection may therefore be particularly important to further improve post-HTX survival in amyloidosis patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
June 2023 2023 |
|---|---|
| Erschienen: |
June 2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
The journal of heart and lung transplantation - 42(2023), 6 vom: Juni, Seite 778-785 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Volz, Martin J. [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Online verfügbar: 12. Januar 2023, Artikelversion: 15. Mai 2023 Gesehen am 15.08.2023 |
|---|
| Umfang: |
Illustrationen 8 |
|---|
| doi: |
10.1016/j.healun.2023.01.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1856211630 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 1856211630 | ||
| 003 | DE-627 | ||
| 005 | 20240329080237.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230815s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.healun.2023.01.001 |2 doi | |
| 035 | |a (DE-627)1856211630 | ||
| 035 | |a (DE-599)KXP1856211630 | ||
| 035 | |a (OCoLC)1425212976 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Volz, Martin J. |e verfasserin |0 (DE-588)1221647512 |0 (DE-627)1738963454 |4 aut | |
| 245 | 1 | 0 | |a Outcomes in patients with cardiac amyloidosis undergoing heart transplantation |b the eurotransplant experience |c Martin J. Kraus, Jacqueline M. Smits, Anna L. Meyer, Agita Strelniece, Arne van Kins, Udo Boeken, Alexander Reinecke, Zdenek Provaznik, Oliver Van Caenegem, Arnaud Ancion, Michael Berchtold-Herz, Johan J.A. Van Cleemput, Axel Haverich, Guenther Laufer, Jan Gummert, Matthias Karck, Gregor Warnecke, Philip W. Raake, Norbert Frey, and Michael M. Kreusser |
| 264 | 1 | |c June 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 12. Januar 2023, Artikelversion: 15. Mai 2023 | ||
| 500 | |a Gesehen am 15.08.2023 | ||
| 520 | |a Background - When advanced heart failure occurs in cardiac amyloidosis, prognosis is poor. In this setting heart transplantation (HTX) is a treatment option for selected patients. We here present the results of post-transplantation outcomes in cardiac amyloidosis within the Eurotransplant area, investigating possible predictors of survival. - Methods - Of 115 patients undergoing HTX due to cardiac amyloidosis in the Eurotransplant region between November 1987 and May 2020, detailed assessment prior to transplantation was available in 85 patients. The present study was conducted in a retrospective approach. Primary endpoint was mortality after HTX. Baseline variables were entered in a Cox proportional hazards model with the primary endpoint as a dependent variable. - Results - Median overall survival following HTX was 6.3 years in the overall collective and the subgroup. Univariate Cox proportional hazards model revealed a significant relationship between overall survival and the transplantation period (2008 to 2020 vs 1987 to 2007; median survival 9.7 years vs 1.8 years, hazard ratio 0.45, p = 0.01). Further predictors were albumin concentration (hazard ratio 0.92, p < 0.001), and systolic blood pressure (hazard ratio 0.96, p < 0.001). The transplant period as well as albumin concentration remained significant independent predictors in the AL sub cohort in a multivariate Cox proportional hazards model. - Conclusions - HTX is a viable treatment option for patients at an advanced stage of cardiac amyloidosis as overall survival after transplantation has improved in the modern age. Patients at a very advanced stage of the disease, indicated by low serum albumin and blood pressure, show worse outcomes following HTX. Optimal timing and careful patient selection may therefore be particularly important to further improve post-HTX survival in amyloidosis patients. | ||
| 700 | 1 | |a Smits, Jacqueline M. |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Anna L. |d 1977- |e verfasserin |0 (DE-588)130213896 |0 (DE-627)495058912 |0 (DE-576)298066866 |4 aut | |
| 700 | 1 | |a Strelniece, Agita |e verfasserin |4 aut | |
| 700 | 1 | |a van Kins, Arne |e verfasserin |4 aut | |
| 700 | 1 | |a Boeken, Udo |e verfasserin |4 aut | |
| 700 | 1 | |a Reinecke, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Provaznik, Zdenek |e verfasserin |4 aut | |
| 700 | 1 | |a Van Caenegem, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Ancion, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Berchtold-Herz, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Van Cleemput, Johan J. A. |e verfasserin |4 aut | |
| 700 | 1 | |a Haverich, Axel |e verfasserin |4 aut | |
| 700 | 1 | |a Laufer, Guenther |e verfasserin |4 aut | |
| 700 | 1 | |a Gummert, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Karck, Matthias |d 1961- |e verfasserin |0 (DE-588)130833525 |0 (DE-627)505909340 |0 (DE-576)298366169 |4 aut | |
| 700 | 1 | |a Warnecke, Gregor |d 1974- |e verfasserin |0 (DE-588)125001517 |0 (DE-627)370699629 |0 (DE-576)294612823 |4 aut | |
| 700 | 1 | |a Raake, Philip |d 1975- |e verfasserin |0 (DE-588)129151246 |0 (DE-627)390021725 |0 (DE-576)297510568 |4 aut | |
| 700 | 1 | |a Frey, Norbert |e verfasserin |0 (DE-588)141244976 |0 (DE-627)625824075 |0 (DE-576)322969514 |4 aut | |
| 700 | 1 | |a Kreußer, Michael |d 1980- |e verfasserin |0 (DE-588)132382385 |0 (DE-627)521949424 |0 (DE-576)260798495 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of heart and lung transplantation |d Amsterdam [u.a.] : Elsevier Science, 1999 |g 42(2023), 6 vom: Juni, Seite 778-785 |h Online-Ressource |w (DE-627)306659743 |w (DE-600)1500494-6 |w (DE-576)260773786 |x 1557-3117 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:6 |g month:06 |g pages:778-785 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.healun.2023.01.001 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1053249823000013 |x Verlag |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_4037 | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 6 |c 6 |h 778-785 |g 8 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 4366346958 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 15-08-23 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2023 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_20 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_8 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1738963497 |a Volz, Martin J. | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)169133667X |a Zentrum für Innere Medizin (Krehl Klinik) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_1 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s p |0 (DE-627)1764998553 |a Meyer, Anna L. | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)1416740848 |a Chirurgische Universitätsklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |a pos_3 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s p |0 (DE-627)1449896383 |a Karck, Matthias | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s k |0 (DE-627)1416740848 |a Chirurgische Universitätsklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |a pos_16 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s p |0 (DE-627)1762851679 |a Warnecke, Gregor | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s k |0 (DE-627)1416740848 |a Chirurgische Universitätsklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |a pos_17 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s p |0 (DE-627)1477753117 |a Raake, Philip | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s k |0 (DE-627)169133667X |a Zentrum für Innere Medizin (Krehl Klinik) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s s |a pos_18 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s p |0 (DE-627)1515274373 |a Frey, Norbert | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s k |0 (DE-627)169133667X |a Zentrum für Innere Medizin (Krehl Klinik) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s s |a pos_19 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s p |0 (DE-627)148532937X |a Kreußer, Michael | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s s |a pos_20 | ||